TapewireFind a company

person · Reporting owner

Sherman Michael A.

Disclosed activity across 6 companies

Tapewire entity
69775
SEC CIK
0001509463

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Aktis Oncology, Inc.AKTS · Entity 4711DirectorJanuary 08, 2026January 09, 2026
Werewolf Therapeutics, Inc.HOWL · Entity 7244DirectorJune 12, 2025June 13, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aktis Oncology, Inc.

Report date January 08, 2026 · Filed January 09, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.14 · Expires 2035-10-08DirectNot disclosed Reported balance Holding disclosure · report date 2026-01-08 · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · Balance Not disclosed

F1: 25% of the original number of shares subject to the option shall vest on August 1, 2026, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-01-07DirectNot disclosed Reported balance Holding disclosure · report date 2026-01-08 · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · Balance Not disclosed

F2: The number of shares subject to the option shall vest in full on January 8, 2027, subject to the Reporting Person's continuous service through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 25% of the original number of shares subject to the option shall vest on August 1, 2026, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

F2: The number of shares subject to the option shall vest in full on January 8, 2027, subject to the Reporting Person's continuous service through such vesting date.

Werewolf Therapeutics, Inc.

Report date June 12, 2025 · Filed June 13, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.29 · Expires 2035-06-11Direct27,000 Reported balance After 2025-06-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2025-06-12 · Grant · Acquired 27,000 · Balance 27,000

F1: The option was granted on June 12, 2025. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director.

Filing footnotes · ownership attribution and instrument terms

F1: The option was granted on June 12, 2025. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

BIOSPECIFICS TECHNOLOGIES CORP

Report date December 02, 2020 · Filed December 02, 2020

Section 16 reporting ended · disclosed 2020-12-02. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common Stock, $0.001 par valueSEC Table I · non-derivativeDirect0 Reported balance After 2020-12-02 transaction · row 1
1 source row

Row 1 · 2020-12-02 · Disposition to issuer · Disposed 2,018 · Balance 0

F1: Upon the consummation of the merger (the "Merger") contemplated by that certain Agreement and Plan of Merger, by and among BioSpecifics Technologies Corp., Endo International plc, and Beta Acquisition Corp., dated October 19, 2020 (the "Merger Agreement"), 2,018 outstanding restricted stock units ("RSUs") were canceled in exchange for a cash payment of $178,593.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the RSUs, by (y) the offer price ($88.50).

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.63 · Expires 2030-05-01Direct0 Reported balance After 2020-12-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2020-12-02 · Disposition to issuer · Disposed 6,000 · Balance 0

F2: Upon the consummation of the Merger, pursuant to the Merger Agreement, the stock options, which provided for vesting in three equal annual installments following the grant date (May 1, 2020), were canceled in exchange for a cash payment of $197,220.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the stock options by (y) the amount by which the offer price ($88.50) exceeds the per share exercise price of such stock option.

Filing footnotes · ownership attribution and instrument terms

F1: Upon the consummation of the merger (the "Merger") contemplated by that certain Agreement and Plan of Merger, by and among BioSpecifics Technologies Corp., Endo International plc, and Beta Acquisition Corp., dated October 19, 2020 (the "Merger Agreement"), 2,018 outstanding restricted stock units ("RSUs") were canceled in exchange for a cash payment of $178,593.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the RSUs, by (y) the offer price ($88.50).

F2: Upon the consummation of the Merger, pursuant to the Merger Agreement, the stock options, which provided for vesting in three equal annual installments following the grant date (May 1, 2020), were canceled in exchange for a cash payment of $197,220.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the stock options by (y) the amount by which the offer price ($88.50) exceeds the per share exercise price of such stock option.

CHIMERIX INC

Report date April 21, 2025 · Filed April 21, 2025

Section 16 reporting ended · disclosed 2025-04-21. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Michael A Sherman Trust Dated June 29, 20070 Reported balance After 2025-04-21 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 1 · 2025-04-21 · Disposition to issuer · Disposed 87,000 · Balance 0

F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2]

F2: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time , each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes.

Common StockSEC Table I · non-derivativeIndirectBy Sherman Investors LLC0 Reported balance After 2025-04-21 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 2 · 2025-04-21 · Disposition to issuer · Disposed 102,995 · Balance 0

F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2]

F2: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time , each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes.

Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2025-04-21 transaction · row 3
1 source row

Row 3 · 2025-04-21 · Disposition to issuer · Disposed 233,413 · Balance 0

F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2]

F2: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time , each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes.

F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.09 · Expires 2029-04-07Direct0 Reported balance After 2025-04-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2025-04-21 · Disposition to issuer · Disposed 1,150,000 · Balance 0

F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.08 · Expires 2030-01-20Direct0 Reported balance After 2025-04-21 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2025-04-21 · Disposition to issuer · Disposed 632,500 · Balance 0

F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.28 · Expires 2031-01-21Direct0 Reported balance After 2025-04-21 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2025-04-21 · Disposition to issuer · Disposed 700,000 · Balance 0

F4: Pursuant to the Merger Agreement, each option to purchase Shares other than an In the Money Option that is then outstanding and unexercised, whether or not vested, was cancelled at the Effective Time with no consideration payable in respect thereof.

Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.62 · Expires 2032-01-17Direct0 Reported balance After 2025-04-21 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2025-04-21 · Disposition to issuer · Disposed 875,000 · Balance 0

F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.97 · Expires 2033-01-16Direct0 Reported balance After 2025-04-21 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2025-04-21 · Disposition to issuer · Disposed 557,050 · Balance 0

F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.89 · Expires 2034-06-19Direct0 Reported balance After 2025-04-21 transaction · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · 2025-04-21 · Disposition to issuer · Disposed 60,000 · Balance 0

F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2]

F2: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time , each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes.

F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

F4: Pursuant to the Merger Agreement, each option to purchase Shares other than an In the Money Option that is then outstanding and unexercised, whether or not vested, was cancelled at the Effective Time with no consideration payable in respect thereof.

ENDOCYTE INC

Report date December 21, 2018 · Filed December 21, 2018

Section 16 reporting ended · disclosed 2018-12-21. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2018-12-21 transaction · row 1 Sequence does not reconcile; account continuity is unresolved.
1 source row

Row 1 · 2018-12-21 · Disposition to issuer · Disposed 243,739 · Balance 0

F1: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes.

Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2018-12-21 transaction · row 3 Sequence does not reconcile; account continuity is unresolved.
1 source row

Row 3 · 2018-12-21 · Disposition to issuer · Disposed 7,188 · Balance 0

F2: This restricted stock unit ("RSU") award, which originally consisted of 14,375 RSUs and of which 7,187 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 4, 2017 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.

Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2018-12-21 transaction · row 4 Sequence does not reconcile; account continuity is unresolved.
1 source row

Row 4 · 2018-12-21 · Disposition to issuer · Disposed 5,000 · Balance 0

F3: This RSU award, which originally consisted of 10,000 RSUs and of which 5,000 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on June 16, 2017 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.

Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2018-12-21 transaction · row 5 Sequence does not reconcile; account continuity is unresolved.
1 source row

Row 5 · 2018-12-21 · Disposition to issuer · Disposed 23,438 · Balance 0

F4: This RSU award, which originally consisted of 31,250 RSUs and of which 7,812 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 2, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.

Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2018-12-21 transaction · row 6 Sequence does not reconcile; account continuity is unresolved.
1 source row

Row 6 · 2018-12-21 · Disposition to issuer · Disposed 62,500 · Balance 0

F5: This RSU award, which originally consisted of 125,000 RSUs and of which 62,500 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/2 annually over a period of 2 years beginning on October 4, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.

Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2018-12-21 transaction · row 7 Sequence does not reconcile; account continuity is unresolved.
1 source row

Row 7 · 2018-12-21 · Disposition to issuer · Disposed 37,500 · Balance 0

F6: This RSU award provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 8, 2019 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.

Common StockSEC Table I · non-derivativeIndirectBy Sherman Investors, LLC0 Reported balance After 2018-12-21 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 2 · 2018-12-21 · Disposition to issuer · Disposed 19,919 · Balance 0

F1: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.05 · Expires 2021-04-14Direct0 Reported balance After 2018-12-21 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2018-12-21 · Disposition to issuer · Disposed 20,800 · Balance 0

F7: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.55 · Expires 2022-02-28Direct0 Reported balance After 2018-12-21 transaction · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · 2018-12-21 · Disposition to issuer · Disposed 74,998 · Balance 0

F7: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.86 · Expires 2023-02-19Direct0 Reported balance After 2018-12-21 transaction · row 10 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 10 · 2018-12-21 · Disposition to issuer · Disposed 58,719 · Balance 0

F7: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.11 · Expires 2024-02-06Direct0 Reported balance After 2018-12-21 transaction · row 11 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 11 · 2018-12-21 · Disposition to issuer · Disposed 36,000 · Balance 0

F7: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.10 · Expires 2025-02-04Direct0 Reported balance After 2018-12-21 transaction · row 12 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 12 · 2018-12-21 · Disposition to issuer · Disposed 86,247 · Balance 0

F7: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.18 · Expires 2026-02-04Direct0 Reported balance After 2018-12-21 transaction · row 13 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 13 · 2018-12-21 · Disposition to issuer · Disposed 86,248 · Balance 0

F8: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 4, 2017. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.68 · Expires 2026-06-16Direct0 Reported balance After 2018-12-21 transaction · row 14 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 14 · 2018-12-21 · Disposition to issuer · Disposed 60,000 · Balance 0

F9: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on June 16, 2017. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.16 · Expires 2027-02-02Direct0 Reported balance After 2018-12-21 transaction · row 15 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 15 · 2018-12-21 · Disposition to issuer · Disposed 187,500 · Balance 0

F10: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 2, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.01 · Expires 2028-02-08Direct0 Reported balance After 2018-12-21 transaction · row 16 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 16 · 2018-12-21 · Disposition to issuer · Disposed 225,000 · Balance 0

F11: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 8, 2019. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes.

F2: This restricted stock unit ("RSU") award, which originally consisted of 14,375 RSUs and of which 7,187 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 4, 2017 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.

F3: This RSU award, which originally consisted of 10,000 RSUs and of which 5,000 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on June 16, 2017 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.

F4: This RSU award, which originally consisted of 31,250 RSUs and of which 7,812 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 2, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.

F5: This RSU award, which originally consisted of 125,000 RSUs and of which 62,500 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/2 annually over a period of 2 years beginning on October 4, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.

F6: This RSU award provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 8, 2019 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.

F7: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

F8: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 4, 2017. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

F9: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on June 16, 2017. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

F10: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 2, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

F11: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 8, 2019. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

Mead Johnson Nutrition Co

Report date June 15, 2017 · Filed June 15, 2017

Section 16 reporting ended · disclosed 2017-06-15. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2017-06-15 transaction · row 1
1 source row

Row 1 · 2017-06-15 · Disposition to issuer · Disposed 4,051 · Balance 0

F1: Pursuant to the Agreement and Plan of Merger, dated February 10, 2017, by and among Mead Johnson Nutrition Company ("MJN"), Reckitt Benckiser Group plc, and Marigold Merger Sub, Inc. (the "Merger Agreement"), at the effective time of the merger, each share of MJN common stock held by the reporting person was converted into the right to receive a cash payment equal to $90.00 per share.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2017-06-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2017-06-15 · Disposition to issuer · Disposed 1,709 · Balance 0

F2: Each restricted stock unit ("RSU") represents the contingent right to receive one share of common stock.

F3: This RSU was originally scheduled to vest on February 28, 2018. Pursuant to the Merger Agreement, at the effective time of the merger, the RSUs held by the reporting person vested and were cancelled in exchange for a lump-sum cash payment equal to the product of (i) the number of shares of common stock subject to such RSU immediately prior to the effective time of the merger and (ii) $90.00 per share.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated February 10, 2017, by and among Mead Johnson Nutrition Company ("MJN"), Reckitt Benckiser Group plc, and Marigold Merger Sub, Inc. (the "Merger Agreement"), at the effective time of the merger, each share of MJN common stock held by the reporting person was converted into the right to receive a cash payment equal to $90.00 per share.

F2: Each restricted stock unit ("RSU") represents the contingent right to receive one share of common stock.

F3: This RSU was originally scheduled to vest on February 28, 2018. Pursuant to the Merger Agreement, at the effective time of the merger, the RSUs held by the reporting person vested and were cancelled in exchange for a lump-sum cash payment equal to the product of (i) the number of shares of common stock subject to such RSU immediately prior to the effective time of the merger and (ii) $90.00 per share.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 12, 2025 Filed Jun 13, 2025 16:10 UTC Werewolf Therapeutics, Inc. HOWL · Entity 7244 GrantStock Option (right to buy) · Derivative 27,000 $0.00 Strike: $1.29 $0.00
Disclosure

SEC source: 0000950170-25-086169 · ownership.xml · derivative · entry 1

Sherman Michael A. · CIK 0001509463 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,000

Underlying: Common Stock · 27,000 shares

Expires 2035-06-11

F1 · derivative.exercise_date: The option was granted on June 12, 2025. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director.

Read SEC document
April 21, 2025 Filed Apr 21, 2025 16:16 UTC CHIMERIX INC CMRX · Entity 80651 Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative 60,000 Not disclosed Strike: $0.89 Not disclosed
Disclosure

SEC source: 0001415889-25-011081 · form4-04212025_080438.xml · derivative · entry 9

Sherman Michael A. · CIK 0001509463 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 60,000 shares

Expires 2034-06-19

F3 · price: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

Read SEC document
April 21, 2025 Filed Apr 21, 2025 16:16 UTC CHIMERIX INC CMRX · Entity 80651 Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative 557,050 Not disclosed Strike: $1.97 Not disclosed
Disclosure

SEC source: 0001415889-25-011081 · form4-04212025_080438.xml · derivative · entry 8

Sherman Michael A. · CIK 0001509463 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 557,050 shares

Expires 2033-01-16

F3 · price: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

Read SEC document
April 21, 2025 Filed Apr 21, 2025 16:16 UTC CHIMERIX INC CMRX · Entity 80651 Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative 875,000 Not disclosed Strike: $5.62 Not disclosed
Disclosure

SEC source: 0001415889-25-011081 · form4-04212025_080438.xml · derivative · entry 7

Sherman Michael A. · CIK 0001509463 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 875,000 shares

Expires 2032-01-17

F3 · price: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

Read SEC document
April 21, 2025 Filed Apr 21, 2025 16:16 UTC CHIMERIX INC CMRX · Entity 80651 Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative 700,000 Not disclosed Strike: $9.28 Not disclosed
Disclosure

SEC source: 0001415889-25-011081 · form4-04212025_080438.xml · derivative · entry 6

Sherman Michael A. · CIK 0001509463 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 700,000 shares

Expires 2031-01-21

F4 · price: Pursuant to the Merger Agreement, each option to purchase Shares other than an In the Money Option that is then outstanding and unexercised, whether or not vested, was cancelled at the Effective Time with no consideration payable in respect thereof.

F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase Shares other than an In the Money Option that is then outstanding and unexercised, whether or not vested, was cancelled at the Effective Time with no consideration payable in respect thereof.

Read SEC document
April 21, 2025 Filed Apr 21, 2025 16:16 UTC CHIMERIX INC CMRX · Entity 80651 Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative 632,500 Not disclosed Strike: $2.08 Not disclosed
Disclosure

SEC source: 0001415889-25-011081 · form4-04212025_080438.xml · derivative · entry 5

Sherman Michael A. · CIK 0001509463 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 632,500 shares

Expires 2030-01-20

F3 · price: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

Read SEC document
April 21, 2025 Filed Apr 21, 2025 16:16 UTC CHIMERIX INC CMRX · Entity 80651 Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative 1,150,000 Not disclosed Strike: $2.09 Not disclosed
Disclosure

SEC source: 0001415889-25-011081 · form4-04212025_080438.xml · derivative · entry 4

Sherman Michael A. · CIK 0001509463 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,150,000 shares

Expires 2029-04-07

F3 · price: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

Read SEC document
April 21, 2025 Filed Apr 21, 2025 16:16 UTC CHIMERIX INC CMRX · Entity 80651 Disposition to issuerCommon Stock 233,413 $8.55 $1,995,681.15
Disclosure

SEC source: 0001415889-25-011081 · form4-04212025_080438.xml · nonDerivative · entry 3

Sherman Michael A. · CIK 0001509463 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2]

F2 · shares: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time , each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes.

F3 · shares: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

Read SEC document
April 21, 2025 Filed Apr 21, 2025 16:16 UTC CHIMERIX INC CMRX · Entity 80651 Disposition to issuerCommon Stock 102,995 $8.55 $880,607.25
Disclosure

SEC source: 0001415889-25-011081 · form4-04212025_080438.xml · nonDerivative · entry 2

Sherman Michael A. · CIK 0001509463 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sherman Investors LLC

Disclosed balance after: 0

F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2]

F2 · shares: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time , each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes.

Read SEC document
April 21, 2025 Filed Apr 21, 2025 16:16 UTC CHIMERIX INC CMRX · Entity 80651 Disposition to issuerCommon Stock 87,000 $8.55 $743,850.00
Disclosure

SEC source: 0001415889-25-011081 · form4-04212025_080438.xml · nonDerivative · entry 1

Sherman Michael A. · CIK 0001509463 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Michael A Sherman Trust Dated June 29, 2007

Disclosed balance after: 0

F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2]

F2 · shares: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time , each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes.

Read SEC document
June 20, 2024 Filed Jun 21, 2024 11:05 UTC CHIMERIX INC CMRX · Entity 80651 GrantStock Option (Right to Buy) · Derivative 60,000 $0.00 Strike: $0.89 $0.00
Disclosure

SEC source: 0001415889-24-017766 · form4-06212024_030648.xml · derivative · entry 1

Sherman Michael A. · CIK 0001509463 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2034-06-19

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2024 annual stockholder meeting.

Read SEC document
May 24, 2024 Filed May 24, 2024 19:45 UTC Werewolf Therapeutics, Inc. HOWL · Entity 7244 GrantStock Option (right to buy) · Derivative 17,500 $0.00 Strike: $4.88 $0.00
Disclosure

SEC source: 0000950170-24-064834 · ownership.xml · derivative · entry 1

Sherman Michael A. · CIK 0001509463 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2034-05-23

F1 · derivative.exercise_date: The option was granted on May 24, 2024. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director.

Read SEC document
June 21, 2023 Filed Jun 23, 2023 16:48 UTC Werewolf Therapeutics, Inc. HOWL · Entity 7244 GrantStock Option (right to buy) · Derivative 13,200 $0.00 Strike: $2.81 $0.00
Disclosure

SEC source: 0000899243-23-016373 · doc4.xml · derivative · entry 1

Sherman Michael A. · CIK 0001509463 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,200

Underlying: Common Stock · 13,200 shares

Expires 2033-06-20

F1 · derivative.exercise_date: The option was granted on June 21, 2023. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director.

Read SEC document
May 12, 2023 Filed May 16, 2023 16:05 UTC CHIMERIX INC CMRX · Entity 80651 PurchaseCommon Stock 75,015 $1.12 $84,121.82
Disclosure

SEC source: 0001209191-23-029760 · doc4.xml · nonDerivative · entry 2

Sherman Michael A. · CIK 0001509463 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Michael A Sherman Trust Dated June 29, 2007

Disclosed balance after: 87,000

Read SEC document
May 12, 2023 Filed May 16, 2023 16:05 UTC CHIMERIX INC CMRX · Entity 80651 PurchaseCommon Stock 11,985 $1.13 $13,529.87
Disclosure

SEC source: 0001209191-23-029760 · doc4.xml · nonDerivative · entry 1

Sherman Michael A. · CIK 0001509463 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Michael A Sherman Trust Dated June 29, 2007

Disclosed balance after: 11,985

Read SEC document
January 17, 2023 Filed Jan 19, 2023 21:46 UTC CHIMERIX INC CMRX · Entity 80651 GrantStock Option (Right to Buy) · Derivative 557,050 $0.00 Strike: $1.97 $0.00
Disclosure

SEC source: 0001209191-23-004145 · doc4.xml · derivative · entry 3

Sherman Michael A. · CIK 0001509463 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 557,050

Underlying: Common Stock · 557,050 shares

Expires 2033-01-16

F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant.

Read SEC document
January 17, 2023 Filed Jan 19, 2023 21:46 UTC CHIMERIX INC CMRX · Entity 80651 GrantCommon Stock 92,950 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-004145 · doc4.xml · nonDerivative · entry 1

Sherman Michael A. · CIK 0001509463 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 222,995

F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards ("RSUs"), each one of which represents a contingent right to receive one share of the Issuer's common stock. 23,237 shares subject to the RSUs will vest on the one-year anniversary of the date of grant, 23,237 shares subject to the RSUs will vest on the second-year anniversary of the date of grant, 23,237 shares subject to the RSUs will vest on the third-year anniversary of the date of grant, and 23,239 shares subject to the RSUs will vest on the fourth-year anniversary of the date of grant.

F2 · balance_after: Includes 4,681 shares acquired under the Issuer's Employee Stock Purchase Plan on September 9, 2022.

Read SEC document
July 25, 2022 Filed Jul 26, 2022 21:25 UTC CHIMERIX INC CMRX · Entity 80651 Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative 100,000 $0.00 Strike: $2.09 $0.00
Disclosure

SEC source: 0001209191-22-043240 · doc4.xml · derivative · entry 2

Sherman Michael A. · CIK 0001509463 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,150,000

Underlying: Common Stock · 100,000 shares

Expires 2029-04-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

Read SEC document
July 25, 2022 Filed Jul 26, 2022 21:25 UTC CHIMERIX INC CMRX · Entity 80651 Exercise / conversionCommon Stock 100,000 $2.09 $209,000.00
Disclosure

SEC source: 0001209191-22-043240 · doc4.xml · nonDerivative · entry 1

Sherman Michael A. · CIK 0001509463 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,364

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 5,147 shares acquired under the Issuer's Employee Stock Purchase Plan (the "ESPP") on September 10, 2020, 5,147 shares acquired under the Issuer's ESPP on March 10, 2021, 5,147 shares acquired under the Issuer's ESPP on September 10, 2021 and 5,233 shares acquired under the Issuer's ESPP on March 10, 2022.

Read SEC document
July 25, 2022 Filed Jul 27, 2022 13:46 UTC Amendment CHIMERIX INC CMRX · Entity 80651 Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative 100,000 $0.00 Strike: $2.09 $0.00
Disclosure

SEC source: 0001209191-22-043250 · doc4a.xml · derivative · entry 3

Sherman Michael A. · CIK 0001509463 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,150,000

Underlying: Common Stock · 100,000 shares

Expires 2029-04-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

Read SEC document
July 25, 2022 Filed Jul 27, 2022 13:46 UTC Amendment CHIMERIX INC CMRX · Entity 80651 Exercise / conversionCommon Stock 100,000 $2.09 $209,000.00
Disclosure

SEC source: 0001209191-22-043250 · doc4a.xml · nonDerivative · entry 1

Sherman Michael A. · CIK 0001509463 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,364

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 5,147 shares acquired under the Issuer's Employee Stock Purchase Plan (the "ESPP") on September 10, 2020, 5,147 shares acquired under the Issuer's ESPP on March 10, 2021, 5,147 shares acquired under the Issuer's ESPP on September 10, 2021 and 5,233 shares acquired under the Issuer's ESPP on March 10, 2022.

Read SEC document
June 01, 2022 Filed Jun 3, 2022 16:39 UTC Werewolf Therapeutics, Inc. HOWL · Entity 7244 GrantStock Option (right to buy) · Derivative 11,600 $0.00 Strike: $3.43 $0.00
Disclosure

SEC source: 0000899243-22-020981 · doc4.xml · derivative · entry 1

Sherman Michael A. · CIK 0001509463 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,600

Underlying: Common Stock · 11,600 shares

Expires 2032-05-31

F1 · derivative.exercise_date: The option was granted on June 1, 2022. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director.

Read SEC document
January 18, 2022 Filed Jan 20, 2022 18:53 UTC CHIMERIX INC CMRX · Entity 80651 GrantStock Option (Right to Buy) · Derivative 875,000 $0.00 Strike: $5.62 $0.00
Disclosure

SEC source: 0001209191-22-004177 · doc4.xml · derivative · entry 1

Sherman Michael A. · CIK 0001509463 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 875,000

Underlying: Common Stock · 875,000 shares

Expires 2032-01-17

F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant.

Read SEC document
May 27, 2021 Filed May 28, 2021 08:07 UTC Werewolf Therapeutics, Inc. HOWL · Entity 7244 GrantStock Option (right to buy) · Derivative 23,200 $0.00 Strike: $14.63 $0.00
Disclosure

SEC source: 0001785530-21-000013 · wf-form4_162220363642407.xml · derivative · entry 1

Sherman Michael A. · CIK 0001509463 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,200

Underlying: Common Stock · 23,200 shares

Expires 2031-05-26

F1 · derivative.exercise_date: The option was granted on May 27, 2021. The shares underlying the option vest over three years, with one-third of the shares vesting on the first anniversary of the date of grant and the remaining shares vesting in equal monthly installments thereafter.

Read SEC document
January 22, 2021 Filed Jan 26, 2021 16:40 UTC CHIMERIX INC CMRX · Entity 80651 GrantStock Option (Right to Buy) · Derivative 700,000 $0.00 Strike: $9.28 $0.00
Disclosure

SEC source: 0001209191-21-005380 · doc4.xml · derivative · entry 1

Sherman Michael A. · CIK 0001509463 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 700,000

Underlying: Common Stock · 700,000 shares

Expires 2031-01-21

F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant.

Read SEC document
December 02, 2020 Filed Dec 2, 2020 09:45 UTC BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 Disposition to issuerStock Option (Right to Buy) · Derivative 6,000 $32.87 Strike: $55.63 $197,220.00
Disclosure

SEC source: 0000899243-20-032449 · doc4.xml · derivative · entry 2

Sherman Michael A. · CIK 0001509463 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,000 shares

Expires 2030-05-01

F2 · derivative.exercise_date: Upon the consummation of the Merger, pursuant to the Merger Agreement, the stock options, which provided for vesting in three equal annual installments following the grant date (May 1, 2020), were canceled in exchange for a cash payment of $197,220.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the stock options by (y) the amount by which the offer price ($88.50) exceeds the per share exercise price of such stock option.

Read SEC document
December 02, 2020 Filed Dec 2, 2020 09:45 UTC BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 Disposition to issuerCommon Stock, $0.001 par value 2,018 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-032449 · doc4.xml · nonDerivative · entry 1

Sherman Michael A. · CIK 0001509463 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: Upon the consummation of the merger (the "Merger") contemplated by that certain Agreement and Plan of Merger, by and among BioSpecifics Technologies Corp., Endo International plc, and Beta Acquisition Corp., dated October 19, 2020 (the "Merger Agreement"), 2,018 outstanding restricted stock units ("RSUs") were canceled in exchange for a cash payment of $178,593.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the RSUs, by (y) the offer price ($88.50).

Read SEC document
May 01, 2020 Filed May 4, 2020 18:21 UTC BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 GrantStock Option (Right to Buy) · Derivative 6,000 $0.00 Strike: $55.63 $0.00
Disclosure

SEC source: 0000899243-20-011918 · doc4.xml · derivative · entry 1

Sherman Michael A. · CIK 0001509463 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 6,000 shares

Expires 2030-05-01

F1 · kind: The stock options were granted under the BioSpecifics Technologies Corp. 2019 Omnibus Incentive Compensation Plan.

F2 · derivative.exercise_date: The stock options vest in three equal installments over the three-year period following the date of grant.

Read SEC document
April 13, 2020 Filed Apr 15, 2020 14:28 UTC BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 GrantCommon Stock, $0.001 par value 2,018 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-010756 · doc4.xml · nonDerivative · entry 1

Sherman Michael A. · CIK 0001509463 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,018

F1 · kind: Grant of restricted stock units under the BioSpecifics Technologies Corp. 2019 Omnibus Incentive Compensation Plan. The restricted stock units vest in full one year from the date of grant.

Read SEC document
March 12, 2020 Filed Mar 16, 2020 12:51 UTC CHIMERIX INC CMRX · Entity 80651 PurchaseCommon Stock 72,995 $1.45 $105,652.96
Disclosure

SEC source: 0001209191-20-019140 · doc4.xml · nonDerivative · entry 1

Sherman Michael A. · CIK 0001509463 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Sherman Investors LLC

Disclosed balance after: 102,995

F1 · price: The price reported in Column 4 is weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.37 to $1.41, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.

Read SEC document
January 21, 2020 Filed Jan 23, 2020 16:32 UTC CHIMERIX INC CMRX · Entity 80651 GrantStock Option (Right to Buy) · Derivative 632,500 $0.00 Strike: $2.08 $0.00
Disclosure

SEC source: 0001209191-20-004692 · doc4.xml · derivative · entry 1

Sherman Michael A. · CIK 0001509463 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 632,500

Underlying: Common Stock · 632,500 shares

Expires 2030-01-20

F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant.

Read SEC document
May 20, 2019 Filed May 20, 2019 16:36 UTC CHIMERIX INC CMRX · Entity 80651 PurchaseCommon Stock 30,000 $3.48 $104,316.00
Disclosure

SEC source: 0001209191-19-031416 · doc4.xml · nonDerivative · entry 1

Sherman Michael A. · CIK 0001509463 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Sherman Investors LLC

Disclosed balance after: 30,000

Read SEC document
April 08, 2019 Filed Apr 9, 2019 18:31 UTC CHIMERIX INC CMRX · Entity 80651 GrantEmployee Stock Option (Right to Buy) · Derivative 1,250,000 $0.00 Strike: $2.09 $0.00
Disclosure

SEC source: 0001209191-19-024163 · doc4.xml · derivative · entry 1

Sherman Michael A. · CIK 0001509463 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,250,000

Underlying: Common Stock · 1,250,000 shares

Expires 2029-04-07

F1 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

Read SEC document
December 21, 2018 Filed Dec 21, 2018 12:47 UTC ENDOCYTE INC ECYT · Entity 161591 Disposition to issuerStock Option (right to buy) · Derivative 225,000 $20.99 Strike: $3.01 $4,722,750.00
Disclosure

SEC source: 0001104659-18-074340 · a4.xml · derivative · entry 16

Sherman Michael A. · CIK 0001509463 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 225,000 shares

Expires 2028-02-08

F11 · price: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 8, 2019. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

F11 · derivative.exercise_date: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 8, 2019. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

Read SEC document
December 21, 2018 Filed Dec 21, 2018 12:47 UTC ENDOCYTE INC ECYT · Entity 161591 Disposition to issuerStock Option (right to buy) · Derivative 187,500 $21.84 Strike: $2.16 $4,095,000.00
Disclosure

SEC source: 0001104659-18-074340 · a4.xml · derivative · entry 15

Sherman Michael A. · CIK 0001509463 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 187,500 shares

Expires 2027-02-02

F10 · price: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 2, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

F10 · derivative.exercise_date: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 2, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

Read SEC document
December 21, 2018 Filed Dec 21, 2018 12:47 UTC ENDOCYTE INC ECYT · Entity 161591 Disposition to issuerStock Option (right to buy) · Derivative 60,000 $20.32 Strike: $3.68 $1,219,200.00
Disclosure

SEC source: 0001104659-18-074340 · a4.xml · derivative · entry 14

Sherman Michael A. · CIK 0001509463 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 60,000 shares

Expires 2026-06-16

F9 · price: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on June 16, 2017. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

F9 · derivative.exercise_date: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on June 16, 2017. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

Read SEC document
December 21, 2018 Filed Dec 21, 2018 12:47 UTC ENDOCYTE INC ECYT · Entity 161591 Disposition to issuerStock Option (right to buy) · Derivative 86,248 $20.82 Strike: $3.18 $1,795,683.36
Disclosure

SEC source: 0001104659-18-074340 · a4.xml · derivative · entry 13

Sherman Michael A. · CIK 0001509463 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 86,248 shares

Expires 2026-02-04

F8 · price: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 4, 2017. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

F8 · derivative.exercise_date: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 4, 2017. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

Read SEC document
December 21, 2018 Filed Dec 21, 2018 12:47 UTC ENDOCYTE INC ECYT · Entity 161591 Disposition to issuerStock Option (right to buy) · Derivative 86,247 $18.90 Strike: $5.10 $1,630,068.30
Disclosure

SEC source: 0001104659-18-074340 · a4.xml · derivative · entry 12

Sherman Michael A. · CIK 0001509463 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 86,247 shares

Expires 2025-02-04

F7 · price: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

F7 · derivative.exercise_date: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

Read SEC document
December 21, 2018 Filed Dec 21, 2018 12:47 UTC ENDOCYTE INC ECYT · Entity 161591 Disposition to issuerStock Option (right to buy) · Derivative 36,000 $12.89 Strike: $11.11 $464,040.00
Disclosure

SEC source: 0001104659-18-074340 · a4.xml · derivative · entry 11

Sherman Michael A. · CIK 0001509463 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 36,000 shares

Expires 2024-02-06

F7 · price: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

F7 · derivative.exercise_date: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

Read SEC document
December 21, 2018 Filed Dec 21, 2018 12:47 UTC ENDOCYTE INC ECYT · Entity 161591 Disposition to issuerStock Option (right to buy) · Derivative 58,719 $14.14 Strike: $9.86 $830,286.66
Disclosure

SEC source: 0001104659-18-074340 · a4.xml · derivative · entry 10

Sherman Michael A. · CIK 0001509463 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 58,719 shares

Expires 2023-02-19

F7 · price: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

F7 · derivative.exercise_date: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

Read SEC document
December 21, 2018 Filed Dec 21, 2018 12:47 UTC ENDOCYTE INC ECYT · Entity 161591 Disposition to issuerStock Option (right to buy) · Derivative 74,998 $20.45 Strike: $3.55 $1,533,709.10
Disclosure

SEC source: 0001104659-18-074340 · a4.xml · derivative · entry 9

Sherman Michael A. · CIK 0001509463 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 74,998 shares

Expires 2022-02-28

F7 · price: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

F7 · derivative.exercise_date: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

Read SEC document
December 21, 2018 Filed Dec 21, 2018 12:47 UTC ENDOCYTE INC ECYT · Entity 161591 Disposition to issuerStock Option (right to buy) · Derivative 20,800 $14.95 Strike: $9.05 $310,960.00
Disclosure

SEC source: 0001104659-18-074340 · a4.xml · derivative · entry 8

Sherman Michael A. · CIK 0001509463 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,800 shares

Expires 2021-04-14

F7 · price: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

F7 · derivative.exercise_date: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

Read SEC document
December 21, 2018 Filed Dec 21, 2018 12:47 UTC ENDOCYTE INC ECYT · Entity 161591 Disposition to issuerCommon Stock 37,500 $24.00 $900,000.00
Disclosure

SEC source: 0001104659-18-074340 · a4.xml · nonDerivative · entry 7

Sherman Michael A. · CIK 0001509463 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F6 · price: This RSU award provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 8, 2019 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.

Read SEC document
December 21, 2018 Filed Dec 21, 2018 12:47 UTC ENDOCYTE INC ECYT · Entity 161591 Disposition to issuerCommon Stock 62,500 $24.00 $1,500,000.00
Disclosure

SEC source: 0001104659-18-074340 · a4.xml · nonDerivative · entry 6

Sherman Michael A. · CIK 0001509463 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F5 · price: This RSU award, which originally consisted of 125,000 RSUs and of which 62,500 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/2 annually over a period of 2 years beginning on October 4, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.

Read SEC document
December 21, 2018 Filed Dec 21, 2018 12:47 UTC ENDOCYTE INC ECYT · Entity 161591 Disposition to issuerCommon Stock 23,438 $24.00 $562,512.00
Disclosure

SEC source: 0001104659-18-074340 · a4.xml · nonDerivative · entry 5

Sherman Michael A. · CIK 0001509463 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F4 · price: This RSU award, which originally consisted of 31,250 RSUs and of which 7,812 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 2, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.

Read SEC document
December 21, 2018 Filed Dec 21, 2018 12:47 UTC ENDOCYTE INC ECYT · Entity 161591 Disposition to issuerCommon Stock 5,000 $24.00 $120,000.00
Disclosure

SEC source: 0001104659-18-074340 · a4.xml · nonDerivative · entry 4

Sherman Michael A. · CIK 0001509463 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F3 · price: This RSU award, which originally consisted of 10,000 RSUs and of which 5,000 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on June 16, 2017 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.

Read SEC document
December 21, 2018 Filed Dec 21, 2018 12:47 UTC ENDOCYTE INC ECYT · Entity 161591 Disposition to issuerCommon Stock 7,188 $24.00 $172,512.00
Disclosure

SEC source: 0001104659-18-074340 · a4.xml · nonDerivative · entry 3

Sherman Michael A. · CIK 0001509463 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F2 · price: This restricted stock unit ("RSU") award, which originally consisted of 14,375 RSUs and of which 7,187 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 4, 2017 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.

Read SEC document
December 21, 2018 Filed Dec 21, 2018 12:47 UTC ENDOCYTE INC ECYT · Entity 161591 Disposition to issuerCommon Stock 19,919 $24.00 $478,056.00
Disclosure

SEC source: 0001104659-18-074340 · a4.xml · nonDerivative · entry 2

Sherman Michael A. · CIK 0001509463 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Sherman Investors, LLC

Disclosed balance after: 0

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes.

Read SEC document
December 21, 2018 Filed Dec 21, 2018 12:47 UTC ENDOCYTE INC ECYT · Entity 161591 Disposition to issuerCommon Stock 243,739 $24.00 $5,849,736.00
Disclosure

SEC source: 0001104659-18-074340 · a4.xml · nonDerivative · entry 1

Sherman Michael A. · CIK 0001509463 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes.

Read SEC document
December 17, 2018 Filed Dec 19, 2018 16:13 UTC ENDOCYTE INC ECYT · Entity 161591 Exercise / conversionStock option (right to buy) · Derivative 2 $0.00 Strike: $3.18 $0.00
Disclosure

SEC source: 0001179110-18-014133 · edgar.xml · derivative · entry 20

Sherman Michael A. · CIK 0001509463 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,248

Underlying: Common Stock · 2 shares

Expires 2026-02-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Shares subject to this option vest 1/4 annually over a period of four years beginning February 4, 2017.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.